Adalimumab demonstrated efficacy and safety in the treatment of patients with moderate to severe ulcerative colitis (UC) in the first Brazilian study to demonstrate the effectiveness and safety profile of the therapy in patients with UC.
Adalimumab demonstrated efficacy and safety in the treatment of patients with moderate to severe ulcerative colitis (UC) in the first Brazilian study to demonstrate the effectiveness and safety profile of the therapy in patients with UC.
Katia Cristina Kampa, MD, and colleagues report that clinical remission was observed in approximately 40% of the patients at week 8 and at week 26, and in nearly a quarter of patients after 1 year of follow-up. Clinical response was observed in approximately 50% of the cases and a third of patients reached endoscopic remission. There were significant rates of secondary loss of response to adalimumab, however, followed by dose optimization or drug switching, the researchers report. The findings were published in the December 2017 issue of Arquivos de Gastroenterologia.
The longitudinal observational and retrospective study reports a case series of 36 patients with moderate to severe UC who were being treated with adalimumab in 7 Brazilian referral centers for inflammatory bowel disease (IBD). The data were analyzed from August 2014 to October 2016. The majority of patients had extensive colitis and long-term disease. Approximately a third had previously received infliximab therapy; 91.7% had used corticosteroids at the initiation of adalimumab, and two-thirds were using concomitant azathioprine during adalimumab treatment.
Clinical remission rates were 41.7% at week 8 (using Last Observation Carried Forward [LOCF] and Non-Responder Imputation [NRI] analysis methodology to account for patients who did not complete the full 52 weeks of the study) and 47.2% (LOCF) and 27.8% (NRI) at week 52. The study also reports a clinical response rate of 55.6% at week 8, similar to the pivotal ULTRA I and ULTRA II clinical trials; at week 52, clinical response was observed in 61.1% (LOCF) and 47.2% (NRI) of the cases.
Half of the patients lost clinical response during follow-up, with dose optimization to adalimumab weekly being required in 8 cases. A total of 16.6% of patients underwent colectomy during adalimumab treatment.
The overall rate of adverse events (AEs) was 67.9%, mainly due to infections. The researchers report a predominance of respiratory infections in this group of patients. Only 1 patient developed a non-melanoma skin cancer. None of the patients stopped treatment due to AEs.
The study was limited by having a small number of patients, and these patients had more severe and refractory disease. Many did not complete the 52-week period needed for full evaluation. The researchers were motivated to undertake the study because of the scarcity of real-world data on the use of adalimumab in UC reported in Brazil and Latin America.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.